Key Laboratory for Space Bioscience and Biotechnology, School of Life Sciences, Northwestern Polytechnical University, 127 Youyi West Road, Xi'an, Shaanxi Province 710072, China.
Food Funct. 2020 May 1;11(5):4428-4445. doi: 10.1039/d0fo00128g. Epub 2020 May 6.
The development of probiotics as therapeutic drugs is greatly important for the protection against threats of drug-resistant pathogen infection in both humans and animals. This study showed that Lactobacillus rhamnosus SHA113, previously isolated from breast milk of healthy humans, showed efficient therapeutic effects on infection by drug resistant Escherichia coli QBQ009. In addition to protecting the intestinal barrier via up-regulating the expression of tight junction proteins ZO-1 and occludin, it was also found that (1) both L. rhamnosus SHA113 and E. coli QBQ009 cells caused changes of the epithelial cell cytoskeleton and up-regulated the expression of phagocytosis-related proteins MYH2 in Caco-2 cells; however, only E. coli QBQ009 caused a strong decrease of cell viability. L. rhamnosus SHA113 treatment after E. coli QBQ009 infection significantly restored the damaged intestinal barrier and the changes of the epithelial cell cytoskeleton caused by E. coli QBQ009. (2) L. rhamnosus SHA113 showed a much higher adhesion rate to the intestinal tract and Caco-2 cells than E. coli QBQ009. The presence of E. coli QBQ009 significantly decreased the adhesion rate of L. rhamnosus SHA113, but not in reverse. (3) L. rhamnosus SHA113 had much higher self-coagulation than E. coli, and could strongly co-coagulate with E. coli QBQ009. The viability of E. coli QBQ009 greatly decreased after co-coagulation, while that of L. rhamnosus SHA113 was not influenced. (4) The polysaccharides produced by L. rhamnosus SHA113 significantly decreased the permeability of the intestinal tract and Caco2 cells, but had no remarkable influence on the adhesion rate of E. coli QBQ009. (5) Feeding L. rhamnosus SHA113 caused a significant reduction of Proteobacteria in the cecum of healthy mice, which was not significant in infected and treated mice. In summary, the decreased live pathogen amounts might be one of the decisive factors for the efficient cure of E. coli QBQ009 infection by L. rhamnosus SHA113, and the restoration of the intestinal barrier might be caused by the reduction of pathogens.
益生菌作为治疗药物的发展对于预防人和动物中耐药病原体感染的威胁非常重要。本研究表明,先前从健康人类母乳中分离出的鼠李糖乳杆菌 SHA113 对耐多药大肠杆菌 QBQ009 的感染具有有效的治疗作用。除了通过上调紧密连接蛋白 ZO-1 和闭合蛋白的表达来保护肠道屏障外,还发现:(1)鼠李糖乳杆菌 SHA113 和大肠杆菌 QBQ009 细胞均引起上皮细胞细胞骨架的变化,并在上皮细胞中上调吞噬相关蛋白 MYH2 的表达;然而,只有大肠杆菌 QBQ009 导致细胞活力明显下降。大肠杆菌 QBQ009 感染后用鼠李糖乳杆菌 SHA113 处理,可显著恢复受损的肠道屏障和大肠杆菌 QBQ009 引起的上皮细胞细胞骨架的变化。(2)鼠李糖乳杆菌 SHA113 对肠道和 Caco-2 细胞的黏附率明显高于大肠杆菌 QBQ009。大肠杆菌 QBQ009 的存在显著降低了鼠李糖乳杆菌 SHA113 的黏附率,但反之则不然。(3)鼠李糖乳杆菌 SHA113 的自凝性明显高于大肠杆菌,并且可以与大肠杆菌 QBQ009 强烈共凝。共凝后大肠杆菌 QBQ009 的活力大大降低,而鼠李糖乳杆菌 SHA113 的活力不受影响。(4)鼠李糖乳杆菌 SHA113 产生的多糖显著降低了肠道和 Caco2 细胞的通透性,但对大肠杆菌 QBQ009 的黏附率没有显著影响。(5)给健康小鼠喂食鼠李糖乳杆菌 SHA113 可显著减少盲肠中的变形菌数量,但在感染和治疗后的小鼠中则不明显。总之,活病原体数量的减少可能是鼠李糖乳杆菌 SHA113 有效治愈大肠杆菌 QBQ009 感染的决定性因素之一,而肠道屏障的恢复可能是由病原体减少引起的。